Takeda, Meiji Seika Pharma deal

Takeda granted Meiji Seika exclusive Japanese co-promotion rights to Rozerem ramelteon to treat insomnia. Meiji will begin promotional activities for the melatonin MT1 and MT2 receptors agonist on Oc...